Episode 107

On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Tim Opler and Chris Garabedian open up with a conversation on recent trends in M&A for private biotechs versus public companies and the potential impact of the election year. The hosts also cover the important data readouts from the week, including Alnylam’s positive Phase 3 results for its ATTR drug and Lyell’s report of a patient death in its early-stage CAR T trial. Additional data covered includes Wave’s Huntington data readout, Intellia’s redosing of CRISPR gene editing therapy and Savara’s Phase 3 readout in rare lung disease. In financing news, the hosts recap Curie.bio’s $380M Pro Rata Series A Fund, Formation’s $372M Series D and Recursion’s $200M offering. This leads into a conversation on AI in drug development and how this is an area full of both promise and hype. On the management theme, the group discusses Gingko’s recent layoffs, business model & revenues. Rounding out the show on the management theme, Amylyx’s pivot to license GLP-1 was mentioned as an example of a management team earning credibility for following through on their word. *This episode aired on June 28, 2024.